Antibodies to Interleukin-2 Elicit Selective T Cell Subset Potentiation through Distinct Conformational Mechanisms.

Antibodies to Interleukin-2 Elicit Selective T Cell Subset Potentiation through Distinct Conformational Mechanisms.
复制标题

DOI:
10.1016/j.immuni.2015.04.015
复制
发表时间:
2015-05-19
期刊:
影响因子:
32.4
通讯作者:
Garcia, K. Christopher
Garcia, K. Christopher
中科院分区:
医学1区
文献类型:
--
作者:
Spangler, Jamie B.;Tomala, Jakub;Luca, Vincent C.;Jude, Kevin M.;Dong, Shen;Ring, Aaron M.;Votavova, Petra;Pepper, Marion;Kovar, Marek;Garcia, K. Christopher

文献摘要

参考文献

被引文献

相似文献

白细胞介素-2 (IL-2)是一种调节免疫细胞稳态的多效细胞因子,已被用于治疗一系列疾病,如癌症和自身免疫性疾病。IL-2通过白细胞介素-2受体-β (IL-2Rβ)传递信号:IL-2Rγ异源二聚体在表达高(调节性T细胞,Treg)或低(效应细胞)IL-2Rα (CD25)的细胞上。当与IL-2结合时,某些抗细胞因子抗体优先刺激Treg (JES6-1)或效应(S4B6)细胞的扩张,为靶向疾病治疗提供了一种策略。我们发现JES6-1立体阻断了IL-2:IL-2Rβ和IL-2:IL-2Rγ的相互作用,但也通过有利于IL-2Rαhi Treg细胞的“触发交换”机制变构降低了IL-2:IL-2Rα的亲和力,为IL-2Rαhi细胞激活创造了一个正反馈回路。相反,S4B6立体阻断IL-2:IL-2Rα相互作用,同时构象稳定IL-2:IL-2Rβ相互作用,从而刺激所有IL-2应答的免疫细胞,特别是IL-2Rβhi效应细胞。我们的见解为工程选择性增强治疗性抗体提供了分子蓝图。
Interleukin-2 (IL-2) is a pleiotropic cytokine that regulates immune cell homeostasis, and has been used to treat a range of disorders such as cancer and autoimmune disease. IL-2 signals via interleukin-2 receptor-β (IL-2Rβ):IL-2Rγ heterodimers on cells expressing high (regulatory T cells, Treg) or low (effector cells) amounts of IL-2Rα (CD25). When complexed with IL-2, certain anti-cytokine antibodies preferentially stimulate expansion of Treg (JES6-1) or effector (S4B6) cells, offering a strategy for targeted disease therapy. We found that JES6-1 sterically blocked the IL-2:IL-2Rβ and IL-2:IL-2Rγ interactions, but also allosterically lowered the IL-2:IL-2Rα affinity through a ‘triggered exchange’ mechanism favoring IL-2Rαhi Treg cells, creating a positive feedback loop for IL-2Rαhi cell activation. Conversely, S4B6 sterically blocked the IL-2:IL-2Rα interaction, while also conformationally stabilizing the IL-2:IL-2Rβ interaction, thus stimulating all IL-2 responsive immune cells, particularly IL-2Rβhi effector cells. Our insights provide a molecular blueprint for engineering selectively potentiating therapeutic antibodies.
DOI: 10.1016/j.imbio.2012.02.009
发表时间: 2013-01-01
期刊: IMMUNOBIOLOGY
影响因子: 2.8
作者:
Rojas, Gertrudis;Pupo, Amaury;Sidhu, Sachdev
通讯作者: Sidhu, Sachdev
DOI: 10.1107/s0907444904019158
发表时间: 2004-12-01
影响因子: 2.2
作者:
Emsley, P;Cowtan, K
通讯作者: Cowtan, K
DOI: 10.1073/pnas.0909384107
发表时间: 2010-02-02
影响因子: 11.1
作者:
Letourneau, Sven;van Leeuwen, Ester M. M.;Boyman, Onur
通讯作者: Boyman, Onur
DOI: 10.1038/nprot.2010.5
发表时间: 2010-04
期刊: Nature protocols
影响因子: 14.8
作者:
通讯作者: --
DOI: 10.1126/scitranslmed.3003634
发表时间: 2012-03-28
影响因子: 17.1
作者:
Rosenberg SA
通讯作者: Rosenberg SA